Irreversible Electroporation for Recurrent Pelvic Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center observational cohort using a registry that blends past and future cases. It includes adults with recurrent pelvic tumors treated with IRE who have no other local options available. The study collects retrospective data from December 2012 through April 2025 and will prospectively enroll new cases to compare safety and local tumor control. Primary focus is on safety; secondary aims assess how well IRE can limit tumor recurrence. Patients receive the IRE procedure as the intervention, with outcomes tracked over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Measurable disease described on pre-treatment imaging (CT/MRI/PET-CT) (max 6 weeks prior);
* IRE of a recurrent pelvic tumor;
* Unsuitable for other local therapies (surgery/stereotactic body radiation therapy) as described during the multidisciplinary tumor board;

Exclusion Criteria:

* If the treated tumor was biopsied directly prior to MWA and pathology proves the lesion to represent a benign entity;
* Inadequate or insufficient data registered;
* Inadequate or insufficient follow-up;

Where it's running

• Amsterdam UMC
  Amsterdam, North Holland, Netherlands Recruiting

Study contacts

• Study coordinator: Sonia Triggiani, Radiologist
• Email: sonia.triggiani@policlinico.mi.it
• Phone: +393406763760

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• LY4052031 for advanced or metastatic urothelial and other nectin‑4–expressing solid tumors

  This trial will test whether LY4052031 is safe and can help people with advanced or metastatic urothelial cancer or other solid tumors that express nectin‑4.

  Recruiting at 36 sites Phase 1 Eli Lilly and Company · Duarte, California and 39 other locations · NCT06465069

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.